Related Experiment Video

Updated: Dec 13, 2025

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.8K

Identification of long non-coding RNA SCARNA9L as a novel molecular target for colorectal cancer

Jie Chai1,2, Jianbo Zhang3, Dali Han4

  • 1Department of Internal Medicine-Oncology, Tianjin Medical University, Tianjin 300070, P.R. China.

Oncology Letters
|July 30, 2020
PubMed

Insights

This study identified SCARNA9L as a novel long non-coding RNA (lncRNA) involved in colorectal cancer (CRC). Depleting SCARNA9L inhibited CRC cell proliferation and migration, suggesting its potential as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Colorectal cancer (CRC) remains a significant global health challenge.
  • Identifying novel molecular targets is crucial for effective CRC therapy.
  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.

Purpose of the Study:

  • To analyze microarray data for differentially expressed lncRNAs in human colorectal cancer (CRC) tissues.
  • To identify novel therapeutic targets for CRC based on lncRNA expression.
  • To investigate the functional role of identified lncRNAs in CRC cell behavior.

Main Methods:

  • Microarray analysis of GSE73360 and GSE84984 datasets.
  • Small interfering RNA (siRNA) mediated depletion of lncRNAs in CRC cell lines.
  • In vitro assays including colony formation, wound closure, and Transwell migration assays.

Main Results:

  • SCARNA9L, SLMO2-ATP5E, and LOC100132062 were identified as differentially expressed lncRNAs in CRC.
  • Ablation of SCARNA9L significantly inhibited proliferation and induced cell cycle arrest in SW480 and SW620 CRC cells.
  • Depletion of SCARNA9L suppressed CRC cell migration in vitro.

Conclusions:

  • SCARNA9L plays a potential role in the progression of colorectal cancer.
  • SCARNA9L inhibition impacts key cancer hallmarks like proliferation and migration.
  • SCARNA9L emerges as a potential diagnostic biomarker and therapeutic target for CRC.
Keywords:
CRCSCARNA9Lmicroarraymigrationproliferation

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.8K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

946

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.2K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.9K